Here we present the results of the PADDOCK and PALOMINO trials, which assessed the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of pegcetacoplan in complement inhibitor-naïve patients (PNH patients who have not previously received treatment with the C5 inhibitors eculizumab or ravulizumab). Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.